Question 1

Biosimilars are exactly identical to their reference biologic drugs, just like generic drugs are to chemical drugs.

Accepted Answer

Unlike generic chemical drugs, biosimilars are highly similar but not perfectly identical to their reference biologics due to the natural variability of living biological systems used to produce them.

Question 2

Non-Animal Methodologies (NAMs) mean that drugs are tested directly on humans after running computer simulations.

Accepted Answer

NAMs heavily involve advanced in-vitro biological models like organ-on-a-chip and 3D organoids derived from human stem cells, which mimic human organ function without using living animals.

Question 3

Consider the following statements regarding the Biopharma SHAKTI scheme:
1. It aims to completely ban traditional animal testing for all preclinical trials in India by 2027.
2. The scheme supports the production of biosimilars, which are exact identical copies of reference biologics.
3. It proposes the establishment of a national network of over 1,000 accredited clinical trial sites.
How many of the above statements are correct?

Accepted Answer

(a) Only one — Statement 1 is incorrect because the scheme prioritises a shift to Non-Animal Methodologies (NAMs) but does not completely ban animal testing. Statement 2 is incorrect because biosimilars are highly similar, but not exactly identical copies, due to the natural variability of biological systems. Statement 3 is correct as the scheme funds a network of over 1,000 accredited clinical trial sites.

Question 4

Match List I (Biopharma Terminology) with List II (Description):
List I:
A. Organoids
B. Biosimilars
C. Generic Drugs
D. Organ-on-a-chip

List II:
1. Microfluidic devices lined with living human cells to simulate organ level physiology
2. Exact chemical copies of small-molecule reference drugs
3. Highly similar clinical equivalents of complex biological drugs
4. 3D miniaturised and simplified versions of organs produced in vitro

Select the correct answer:

Accepted Answer

(a) A-4, B-3, C-2, D-1 — Organoids (A) are 3D miniaturised organs produced in vitro (4). Biosimilars (B) are highly similar clinical equivalents of biological drugs (3). Generic drugs (C) are exact chemical copies (2). Organ-on-a-chip (D) utilizes microfluidic devices with human cells (1).

Question 5

Assertion (A): The Biopharma SHAKTI scheme focuses on transitioning from traditional in-vivo animal testing to Non-Animal Methodologies (NAMs) like organoids.
Reason (R): Animal models often fail to accurately predict human responses to complex biologics, leading to high failure rates in human clinical trials.
Select the correct answer:

Accepted Answer

(a) Both A and R are true and R is the correct explanation of A — The assertion is true as the scheme officially prioritises NAMs to replace traditional testing. The reason is also true and correctly explains the assertion: a major scientific driver for adopting NAMs is that human-derived organoids and organ-on-a-chip models predict human drug responses much more accurately than animal models, especially for complex biological medicines.